NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
This article was originally published in The Pink Sheet Daily
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.
You may also be interested in...
EMEA has 60 days to review Tarceva on appeal; the oncologic is approved for treatment of advanced pancreatic cancer in the U.S.
Guidances for some products could be issued by the end of the year under a new rapid review system.
The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.